MedTrace Logo

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood

NCT04011241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-02-22

Study results available
· View outcomes & findings →

Summary

The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test,T) as compared to when given alone as oral single dose (Reference, R).

Conditions

  • Healthy

Interventions

DRUG

BI 1323495

Tablet

DRUG

Itraconazole

Oral solution

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-24
Primary Completion
2019-09-06
Completion
2019-09-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04011241 on ClinicalTrials.gov